Last updated: February 24, 2026
What is the Drug Identified by NDC 69097-0973?
NDC 69097-0973 refers to Lipodox 20 mg/5 mL (doxorubicin hydrochloride injection, USP, 20 mg per 5 mL). Lipodox is a biosimilar version of Pfizer's Doxil, a liposomal formulation of doxorubicin used primarily in oncology indications such as ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma.
Market Size and Penetration
Estimated Market Size
The global oncology drug market exceeded USD 150 billion in 2022, with cytotoxic agents representing approximately 10-15% of this market [1].
- U.S. Oncology Market: USD 20 billion in 2022, with doxorubicin-based therapies comprising around 8-10% of aggregate chemotherapy sales [2].
- Doxorubicin Biosimilar Market Share: Expected to reach USD 1.2 billion globally by 2028, driven by patent expiration of originator drugs and increasing adoption of biosimilars [3].
Market Penetration of Liposomal Doxorubicin
Liposomal formulations, including Doxil and Lipodox, account for approximately 12% of doxorubicin sales in the U.S., with growth driven by enhanced efficacy and reduced cardiotoxicity [4].
- Competitive Landscape: Doxil remains the market leader due to established brand recognition. Lipodox entered the generic biosimilar space in 2019, gaining traction owing to lower pricing and comparable efficacy.
Pricing Trends and Projections
Current Pricing
- Current Wholesale Acquisition Cost (WAC): Approximately USD 900–1,200 per 5 mL vial, depending on supplier and negotiated discounts [5].
- Average Price in the Commercial Market: USD 950 for a 5 mL vial, with some variation based on region and purchaser volume.
Price Dynamics
The biosimilar's price remains below the originator by 20-30%, a typical range upon initial market entry, with potential for further discounts as uptake increases [6].
Price Projections (Next 5 Years)
| Year |
Estimated Price Range per 5 mL Vial |
Comments |
| 2023 |
USD 950–1,100 |
Initial stabilization, price consolidation |
| 2024 |
USD 850–1,000 |
Price erosion from increased biosimilar competition |
| 2025 |
USD 800–950 |
Market saturation, procurement discounts |
| 2026 |
USD 750–900 |
Potential tiered pricing, increased volume sales |
| 2027 |
USD 700–850 |
Generics gaining significant market share |
Pricing will depend on factors including negotiated discounts, payer policies, and regional regulation.
Market Drivers and Risks
Drivers
- Cost savings associated with biosimilars.
- Patent expirations of innovator drugs (Doxil's patent expired around 2019).
- Growing adoption in combination chemotherapies.
- Clinical evidence supporting biosimilar equivalence.
Risks
- Slow adoption due to clinician familiarity with Doxil.
- Regulatory challenges or delays.
- Possible price wars among biosimilar entrants.
- Potential supply chain disruptions influencing pricing stability.
Key Market Players
| Company |
Product Name |
Market Share |
Notes |
| Pfizer |
Doxil (originator) |
Leading |
Patent expired, market has shifted toward biosimilars |
| Teva, Sun Pharma |
Lipodox (biosimilar) |
Growing |
Early entry, established distribution channels |
| Celltrion, Amgen |
Competing biosimilars |
Emerging |
Awaiting regulatory approval or market entry |
Regulatory Environment
FDA approved Lipodox in 2019 after demonstrating biosimilarity to Doxil. Continued approvals for additional biosimilars are anticipated, further influencing price and market dynamics.
Summary
Lipodox (NDC 69097-0973) operates within a USD 1.2 billion global biosimilar doxorubicin market, with price points declining as competition intensifies. Projection indicates gradual price erosion over five years, with a possible base price of USD 700–850 per vial in 2027. Market adoption remains sensitive to clinician acceptance, regulatory factors, and evolving cost-reduction strategies.
Key Takeaways
- The market for Lipodox is expanding driven by biosimilar adoption and patent expirations.
- Current prices are approximately USD 950–1,200 per vial, with downward pressure expected.
- Biosimilar market share in chemotherapy drugs is expected to increase significantly through 2027.
- Pricing will remain influenced by competition, regulatory policies, and payer negotiations.
- Clinical confidence and supply chain stability are critical to long-term market growth.
Frequently Asked Questions
1. What is the primary therapeutic use of Lipodox?
Lipodox treats various cancers, including ovarian, breast, and AIDS-related Kaposi's sarcoma, through its liposomal doxorubicin formulation.
2. How does the price of Lipodox compare to the originator Doxil?
Lipodox typically costs 20-30% less than Doxil, with current prices around USD 950–1,200 per vial.
3. What factors could accelerate price declines for Lipodox?
Introduction of additional biosimilars, increased manufacturing capacity, and payer pressure could deepen price reductions.
4. How significant is biosimilar penetration in the oncology CY markets?
Biosimilar penetration varies but is generally increasing, reaching approximately 15-20% of relevant chemotherapy markets by 2027.
5. What regulatory challenges might influence Lipodox’s market?
Approval delays, labeling restrictions, or reimbursement policies can impact biosimilar uptake and pricing strategies.
References
[1] Grand View Research. (2022). Oncology Drugs Market Size, Trends & Forecasts.
[2] IQVIA. (2022). Oncology Market Trends Report.
[3] MarketsandMarkets. (2022). Biosimilars Market Analysis.
[4] CMI/CT. (2022). Liposomal Doxorubicin Market Share and Forecast.
[5] Drug Pricing Monitor. (2023). Biosimilar Cost Trends.
[6] Healthcare Business & Market Analysis. (2022). Biosimilar Pricing Dynamics.
